TY - JOUR T1 -在停用英夫利昔单抗的克罗恩病患者中，与短期和中长期临床复发风险相关的不同血液蛋白谱:当缓解状态隐藏不同类型的残余疾病活动JF - Gut JO - Gut SP - 443 LP - 450 DO - 10.1136/gutjnl-202 -327321 VL - 72 IS -3 AU - Nicolas Pierre AU - Vân Anh Huynh-Thu AU - Thomas Marichal AU - Matthieu Allez AU - Yoram Bouhnik AU - David Laharie AU - Arnaud Bourreille AU - Jean-Frédéric Colombel AU - Marie-Alice Meuwis AU - Edouard Louis A2 -，目的:尽管克罗恩病(CD)停止抗肿瘤坏死因子α (TNFα)的患者处于持续稳定的缓解状态，但其复发率很高(2年内~50%)。需要对这些患者的生物学特征进行非侵入性描述，以更好地指导抗tnf α停用的决定。在持续无类固醇缓解和停止抗tnf α(英夫利昔单抗)的CD患者(n=102)的血清中，采用接近延伸法测定了92种免疫相关蛋白。如前所述，基于临床复发时间的分层用于描述复发者的不同生物学特征(短期复发者:<6个月vs中长期复发者:>6个月)。蛋白质水平与临床复发时间之间的关系由单变量Cox模型确定。结果中远期复发风险(HR)与血清中主要表达于淋巴细胞的蛋白(LAG3、SH2B3、SIT1;人力资源:2.2 - -4.5;p<0.05)，血清中抗炎因子(IL-10, HSD11B1; HR: 0.2–0.3; p<0.05) and cellular junction proteins (CDSN, CNTNAP2, CXADR, ITGA11; HR: 0.4; p<0.05). The risk of short-term clinical relapse was specifically associated with a high serum level of pro-inflammatory effectors (IL-6, IL12RB1; HR: 3.5–3.6; p<0.05) and a low or high serum level of proteins mainly expressed in antigen presenting cells (CLEC4A, CLEC4C, CLEC7A, LAMP3; HR: 0.4–4.1; p<0.05).Conclusion We identified distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with CD stopping infliximab. These findings constitute an advance for the development of non-invasive biomarkers guiding the decision of anti-TNFα withdrawal.Data are available upon reasonable request. Data supporting the reported results (deidentified individual participant data and raw data of the PEA) can be shared upon request to the corresponding author. All the processed data are available in the supplemental tables. ER -